mannitol inhalation (Rx)Brand and Other Names:Aridol

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

dry powder capsules for inhalation

  • 0mg, 5mg, 10mg, 20mg, and 40mg per kit
more...

Airway Hyperreactivity Assessment

Indicated for the assessment of bronchial hyperresponsiveness in patients who do not have clinically apparent asthma

Administer sequentially increasing doses via inhalation while measuring forced expiratory volume in 1 second (FEV1)

A positive response is achieved when the patient experiences a 15% reduction in FEV1 from (0 mg) baseline (or a 10% incremental reduction in FEV1 between consecutive doses)

Patients with either a positive response to bronchial challenge testing or significant respiratory symptoms should receive a standard dose of a short-acting inhaled beta-agonist and monitored until fully recovered to within baseline

Sequential doses

  • Increased sequential dosing continues until a positive response observed or 635 mg cumulative dose is administered without response (negative test)
  • Dose #1: 0 mg
  • Dose #2: 5 mg
  • Dose #3: 10 mg (cumulative dose 15 mg)
  • Dose #4: 20 mg (cumulative dose 35 mg)
  • Dose #5: 40 mg (cumulative dose 75 mg)
  • Dose #6: 80 mg (cumulative dose 155 mg)
  • Dose #7: 160 mg (cumulative dose 315 mg); may repeat this dose if needed 2 more times for a cumulative dose of 635 mg

Dosage Forms & Strengths

dry powder capsules for inhalation

  • 0mg, 5mg, 10mg, 20mg, and 40mg per kit
more...

Airway Hyperreactivity Assessment

Indicated for the assessment of bronchial hyperresponsiveness in patients who do not have clinically apparent asthma

<6 years: Safety and efficacy not established

6 years or older: As adults

Administer sequentially increasing doses via inhalation while measuring forced expiratory volume in 1 second (FEV1)

A positive response is achieved when the patient experiences a 15% reduction in FEV1 from (0 mg) baseline (or a 10% incremental reduction in FEV1 between consecutive doses)

Patients with either a positive response to bronchial challenge testing or significant respiratory symptoms should receive a standard dose of a short-acting inhaled beta-agonist and monitored until fully recovered to within baseline

Sequential doses

  • Increased sequential dosing continues until a positive response observed or 635 mg cumulative dose is administered without response (negative test)
  • Dose #1: 0 mg
  • Dose #2: 5 mg
  • Dose #3: 10 mg (cumulative dose 15 mg)
  • Dose #4: 20 mg (cumulative dose 35 mg)
  • Dose #5: 40 mg (cumulative dose 75 mg)
  • Dose #6: 80 mg (cumulative dose 155 mg)
  • Dose #7: 160 mg (cumulative dose 315 mg); may repeat this dose if needed 2 more times for a cumulative dose of 635 mg
Next

Interactions

Interaction Checker

mannitol inhalation and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            1-10%

            Headache (6%); children (3%)

            Pharyngolaryngeal pain (2%); children (4%)

            Throat irritation (2%)

            Nausea (2%); children (3%)

            Cough (2%)

            Rhinorrhea (2%)

            Dyspnea (1%)

            Chest discomfort (1%)

            Wheezing (1%)

            Retching (1%)

            Dizziness (1%)

            Previous
            Next

            Warnings

            Black Box Warnings

            Mannitol, the active ingredient, acts as a bronchoconstrictor and may cause severe bronchospasm

            Bronchial challenge testing with mannitol inhalation is for diagnostic purposes only

            Bronchial challenge testing should only be conducted by trained professionals under the supervision of a physician familiar with all aspects of the bronchial challenge test and the management of acute bronchospasm

            Medications (eg, short-acting inhaled beta¬ agonist) and equipment to treat severe bronchospasm must be present in the testing area; if severe bronchospasm occurs it should be treated immediately by administration of a short-acting inhaled beta-agonist

            Because of the potential for severe bronchoconstriction, the bronchial challenge testing with should not be performed in any patient with clinically apparent asthma or very low baseline pulmonary function tests (eg, FEV1 <1-1.5 L or <70% of the predicted values)

            Contraindications

            Hypersensitivity

            Conditions that may be compromised by induced bronchospasm or repeated spirometry maneuvers (eg, aortic or cerebral aneurysm, uncontrolled hypertension, recent myocardial infarction, cerebral vascular accident)

            Cautions

            Not a stand-alone test or a screening test for asthma; bronchial challenge testing should be used only as part of a physician’s overall assessment of asthma

            May cause severe bronchospasm in susceptible patients (see Black Box Warnings)

            If a patient has a 10% or more reduction in FEV1 (from prechallenge FEV1) on administration of the 0 mg capsule, discontinued test administer short-acting inhaled beta-agonist and monitored accordingly

            Patients with either a positive response to bronchial challenge testing with or significant respiratory symptoms should receive a short-acting inhaled beta-agonist

            Caution with conditions that may increase sensitivity to the bronchoconstricting or other potential effects (eg, severe cough, ventilatory impairment, spirometry-induced bronchoconstriction, hemoptysis of unknown origin, pneumothorax, recent abdominal or thoracic surgery, recent intraocular surgery, unstable angina, or active upper or lower respiratory tract infection)

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy Category: C

            Lactation: Unknown whether distributed in breast milk, caution advised

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Half-Life: 4.7 hr

            Absorption: 59%

            Vd: 34.3 L

            Peak Plasma Time: 1.5 hr

            Peak Plasma Concentration: 13 mcg/mL (following 635 mg cumulative dose)

            AUC: 73.15 mcg•hr/mL

            Protein Bound: %

            Metabolism: negligible

            Clearance: 5.1 L/hr

            Excretion: urine (55%) as unchanged drug

            Mechanism of Action

            Mannitol is a sugar alcohol, and when inhaled may cause bronchoconstriction; the precise mechanism by which bronchoconstriction occurs is unknown

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.